Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01959594 · ClinicalTrials.gov registry record · Phase 1
A Study To Observe Safety And Blood Concentrations Of PF-06412562 During And Following The Oral Administration Of Multiple Doses Of PF-06412562 In Healthy Adult Volunteers
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT01959594 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 40 participants.
The verdict
NCT01959594, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
This study is designed to evaluate the safety and plasma concentrations of PF-06412562 in healthy volunteers following three times daily oral dosing of PF-06412562 for 14 days
Interventions
- DRUG 3 mg PF-06412562
- DRUG 10 mg PF-06412562
- DRUG 25 mg PF-06412562
- DRUG PF-06412562 TBD mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2013-11 |
| Est. Completion | 2014-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01959594
The ClinicalTrials.gov registry entry for NCT01959594 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which 3 mg PF-06412562 is the first listed.
NCT01959594 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01959594 about?
NCT01959594 is a clinical study titled "A Study To Observe Safety And Blood Concentrations Of PF-06412562 During And Following The Oral Administration Of Multiple Doses Of PF-06412562 In Healthy Adult Volunteers". This study is designed to evaluate the safety and plasma concentrations of PF-06412562 in healthy volunteers following three times daily oral dosing of PF-06412562 for 14 days
What is the current status of trial NCT01959594?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2013-11. Estimated completion is 2014-03.
What interventions are being tested in trial NCT01959594?
The interventions under investigation include: 3 mg PF-06412562 (DRUG), 10 mg PF-06412562 (DRUG), 25 mg PF-06412562 (DRUG), PF-06412562 TBD mg (DRUG).
Who is sponsoring clinical trial NCT01959594?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.